butyl isothiocyanate has been researched along with Urinary Bladder Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Blaheta, RA; Chun, FK; Cinatl, J; Grein, T; Haferkamp, A; Khadir, SE; Makhatelashvili, N; Mann, J; Maxeiner, S; Rutz, J; Sonnenburg, M; Thomas, A; Tsaur, I; Xie, H | 1 |
1 other study(ies) available for butyl isothiocyanate and Urinary Bladder Neoplasms
Article | Year |
---|---|
Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Topics: Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinases; Cyclins; Deoxycytidine; Gemcitabine; Humans; Isothiocyanates; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2022 |